AIP
MGX icon

Ameritas Investment Partners’s Metagenomi Therapeutics MGX Stock Holding History

Ameritas Investment Partners’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-618
Closed -$840 – 3370
2025
Q1 		$840 Hold
618
– – ﹤0.01% 3109
2024
Q4 		$2.23K Hold
618
– – ﹤0.01% 3094
2024
Q3 		$1.34K Hold
618
– – ﹤0.01% 3108
2024
Q2 		$2.52K Buy
+618
New +$4.25K ﹤0.01% 3088

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameritas Investment Partners's MGX Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 618 shares — an estimated $840 sold.

Ameritas Investment Partners first reported a position in MGX in Q2 2024 and held it in 4 quarters. The position peaked at $2.52K in Q2 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

  • Ameritas Investment Partners reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 618 Metagenomi Therapeutics shares in Q2 2025, an estimated $840.
  • Ameritas Investment Partners first reported a position in Metagenomi Therapeutics in Q2 2024 and held it in 4 quarters.
  • Ameritas Investment Partners's Metagenomi Therapeutics position peaked at $2.52K in Q2 2024.
  • 69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.